Matching articles for "atenolol"

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • May 27, 2024;  (Issue 1703)
American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of hypertension were last published in 2018. Treatment of hypertensive urgencies and emergencies is not discussed...
American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of hypertension were last published in 2018. Treatment of hypertensive urgencies and emergencies is not discussed here.
Med Lett Drugs Ther. 2024 May 27;66(1703):81-8 | Show Full IntroductionHide Full Introduction

Treatment of Atrial Fibrillation

   
The Medical Letter on Drugs and Therapeutics • January 8, 2024;  (Issue 1693)
Atrial fibrillation (AF) is the most common arrhythmia in the world. Risk factor modification, anticoagulation, rhythm control, and rate control are the four pillars of its management. American College of...
Atrial fibrillation (AF) is the most common arrhythmia in the world. Risk factor modification, anticoagulation, rhythm control, and rate control are the four pillars of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines on management of AF were updated recently.
Med Lett Drugs Ther. 2024 Jan 8;66(1693):1-8 | Show Full IntroductionHide Full Introduction

Drugs for Migraine

   
The Medical Letter on Drugs and Therapeutics • June 12, 2023;  (Issue 1678)
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine pain without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to...
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine pain without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine in most patients without vascular disease. Treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):89-96 | Show Full IntroductionHide Full Introduction

Mavacamten (Camzyos) for Obstructive Hypertrophic Cardiomyopathy

   
The Medical Letter on Drugs and Therapeutics • June 13, 2022;  (Issue 1652)
The FDA has approved mavacamten (Camzyos – MyoKardia/BMS), a modulator of cardiac myosin, to improve functional capacity and symptoms in adults with New York Heart Association (NYHA) class II or III...
The FDA has approved mavacamten (Camzyos – MyoKardia/BMS), a modulator of cardiac myosin, to improve functional capacity and symptoms in adults with New York Heart Association (NYHA) class II or III obstructive hypertrophic cardiomyopathy (HCM) who have a baseline left ventricular ejection fraction (LVEF) ≥55%. Mavacamten is the first drug in its class to become available in the US.
Med Lett Drugs Ther. 2022 Jun 13;64(1652):89-91 | Show Full IntroductionHide Full Introduction

Drugs for Migraine

   
The Medical Letter on Drugs and Therapeutics • October 5, 2020;  (Issue 1608)
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine headache without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to...
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine headache without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine headache pain in most patients without vascular disease. Early treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.
Med Lett Drugs Ther. 2020 Oct 5;62(1608):153-60 | Show Full IntroductionHide Full Introduction

Eptinezumab (Vyepti) for Migraine Prevention

   
The Medical Letter on Drugs and Therapeutics • June 1, 2020;  (Issue 1599)
The FDA has approved eptinezumab-jjmr (Vyepti – Lundbeck), a calcitonin gene-related peptide (CGRP) antagonist administered IV once every 3 months, for migraine prevention in adults. It is the fourth...
The FDA has approved eptinezumab-jjmr (Vyepti – Lundbeck), a calcitonin gene-related peptide (CGRP) antagonist administered IV once every 3 months, for migraine prevention in adults. It is the fourth monoclonal antibody to be approved for this indication; erenumab (Aimovig), fremanezumab (Ajovy), and galcanezumab (Emgality), which are all given subcutaneously once monthly (fremanezumab can also be given once every 3 months), were approved earlier.
Med Lett Drugs Ther. 2020 Jun 1;62(1599):85-7 | Show Full IntroductionHide Full Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • May 18, 2020;  (Issue 1598)
Drugs available for treatment of chronic hypertension and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed...
Drugs available for treatment of chronic hypertension and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.
Med Lett Drugs Ther. 2020 May 18;62(1598):73-80 | Show Full IntroductionHide Full Introduction

Drugs for Atrial Fibrillation

   
The Medical Letter on Drugs and Therapeutics • September 9, 2019;  (Issue 1580)
Treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. US guidelines were recently...
Treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. US guidelines were recently updated.
Med Lett Drugs Ther. 2019 Sep 9;61(1580):137-44 | Show Full IntroductionHide Full Introduction

Fremanezumab (Ajovy) and Galcanezumab (Emgality) for Migraine Prevention

   
The Medical Letter on Drugs and Therapeutics • November 5, 2018;  (Issue 1559)
The FDA has approved two subcutaneously injected calcitonin gene-related peptide (CGRP) antagonists, fremanezumab-vfrm (Ajovy – Teva) and galcanezumab-gnlm (Emgality – Lilly), for migraine prevention in...
The FDA has approved two subcutaneously injected calcitonin gene-related peptide (CGRP) antagonists, fremanezumab-vfrm (Ajovy – Teva) and galcanezumab-gnlm (Emgality – Lilly), for migraine prevention in adults. Fremanezumab and galcanezumab are the second and third subcutaneously injected monoclonal antibodies that target the CGRP pathway to be approved by the FDA for this indication; erenumab-aooe (Aimovig), which targets the CGRP receptor, was the first.
Med Lett Drugs Ther. 2018 Nov 5;60(1559):177-80 | Show Full IntroductionHide Full Introduction

Erenumab (Aimovig) for Migraine Prevention

   
The Medical Letter on Drugs and Therapeutics • June 18, 2018;  (Issue 1549)
The FDA has approved erenumab-aooe (Aimovig – Amgen/Novartis), a once-monthly, subcutaneously-injected, monoclonal antibody against the calcitonin gene-related peptide receptor, for preventive...
The FDA has approved erenumab-aooe (Aimovig – Amgen/Novartis), a once-monthly, subcutaneously-injected, monoclonal antibody against the calcitonin gene-related peptide receptor, for preventive treatment of migraine in adults. It is the first drug in its class to be approved by the FDA.
Med Lett Drugs Ther. 2018 Jun 18;60(1549):101-3 | Show Full IntroductionHide Full Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • March 13, 2017;  (Issue 1516)
in the US and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed...
in the US and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.
Med Lett Drugs Ther. 2017 Mar 13;59(1516):41-8 | Show Full IntroductionHide Full Introduction

Drugs for Migraine

   
The Medical Letter on Drugs and Therapeutics • February 13, 2017;  (Issue 1514)
An oral nonopioid analgesic may be sufficient for treatment of mild to moderate migraine without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine. Use...
An oral nonopioid analgesic may be sufficient for treatment of mild to moderate migraine without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine. Use of a triptan early in an attack when pain is still mild to moderate in intensity improves headache response and reduces recurrence rates.
Med Lett Drugs Ther. 2017 Feb 13;59(1514):27-32 | Show Full IntroductionHide Full Introduction

Byvalson - A Beta Blocker/ARB Combination for Hypertension

   
The Medical Letter on Drugs and Therapeutics • September 12, 2016;  (Issue 1503)
The FDA has approved Byvalson (Allergan), a fixed-dose combination of the beta blocker nebivolol (Bystolic) and the angiotensin receptor blocker (ARB) valsartan (Diovan, and generics), for treatment...
The FDA has approved Byvalson (Allergan), a fixed-dose combination of the beta blocker nebivolol (Bystolic) and the angiotensin receptor blocker (ARB) valsartan (Diovan, and generics), for treatment of hypertension. It is the only combination product that contains nebivolol, and the first to combine a beta blocker with an ARB.
Med Lett Drugs Ther. 2016 Sep 12;58(1503):115-7 | Show Full IntroductionHide Full Introduction

Treatment of Atrial Fibrillation

   
The Medical Letter on Drugs and Therapeutics • July 7, 2014;  (Issue 1446)
The treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. New US guidelines for the management of atrial fibrillation have recently been...
The treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. New US guidelines for the management of atrial fibrillation have recently been published.
Med Lett Drugs Ther. 2014 Jul 7;56(1446):53-8 | Show Full IntroductionHide Full Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • May 1, 2014;  (Issue 141)
Most recent guidelines recommend a BP goal of 140/90 mm Hg. For patients ≥60 years old without diabetes or chronic kidney disease, one guideline recommends 150/90 mm Hg both as the drug treatment...
Most recent guidelines recommend a BP goal of 140/90 mm Hg. For patients ≥60 years old without diabetes or chronic kidney disease, one guideline recommends 150/90 mm Hg both as the drug treatment initiation threshold and treatment target; this higher target is controversial, except in patients ≥80 years old.
Treat Guidel Med Lett. 2014 May;12(141):31-8 | Show Full IntroductionHide Full Introduction

Beta-Adrenergic Blockers and Breast Cancer

   
The Medical Letter on Drugs and Therapeutics • January 23, 2012;  (Issue 1382)
Three retrospective studies have recently reported an association between beta-blocker use and a reduction in breast cancer metastasis and recurrence. No prospective, randomized trials have been...
Three retrospective studies have recently reported an association between beta-blocker use and a reduction in breast cancer metastasis and recurrence. No prospective, randomized trials have been published.
Med Lett Drugs Ther. 2012 Jan 23;54(1382):6-7 | Show Full IntroductionHide Full Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • January 1, 2012;  (Issue 113)
Drugs available in the US for treatment of chronic hypertension, with their dosages and adverse effects, are listed in the tables that begin on page 2. Combination products are listed on page 8. Drugs...
Drugs available in the US for treatment of chronic hypertension, with their dosages and adverse effects, are listed in the tables that begin on page 2. Combination products are listed on page 8. Drugs for treatment of hypertensive emergencies are not discussed here. They were reviewed previously.
Treat Guidel Med Lett. 2012 Jan;10(113):1-10 | Show Full IntroductionHide Full Introduction

Drugs for Migraine

   
The Medical Letter on Drugs and Therapeutics • February 1, 2011;  (Issue 102)
Drugs for treatment of migraine are listed in Table 2 on page 9. Drugs for prevention of migraine are listed in Table 3 on page 10. Treatment of migraine in the emergency room, which may involve use of...
Drugs for treatment of migraine are listed in Table 2 on page 9. Drugs for prevention of migraine are listed in Table 3 on page 10. Treatment of migraine in the emergency room, which may involve use of intravenous drugs, is not included here.
Treat Guidel Med Lett. 2011 Feb;9(102):7-12 | Show Full IntroductionHide Full Introduction

Drugs for Thyroid Disorders

   
The Medical Letter on Drugs and Therapeutics • August 1, 2009;  (Issue 84)
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for...
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.
Treat Guidel Med Lett. 2009 Aug;7(84):57-64 | Show Full IntroductionHide Full Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • January 1, 2009;  (Issue 77)
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 2. Combination products are listed on page 9. Drugs...
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 2. Combination products are listed on page 9. Drugs for treatment of hypertensive emergencies are not discussed here. They were reviewed in Treatment Guidelines (volume 1, page 19, December 2002) and in The Medical Letter (volume 50, page 73, September 22, 2008).
Treat Guidel Med Lett. 2009 Jan;7(77):1-10 | Show Full IntroductionHide Full Introduction

Nebivolol (Bystolic) for Hypertension

   
The Medical Letter on Drugs and Therapeutics • March 10, 2008;  (Issue 1281)
Nebivolol (Bystolic - Forest) is a new beta-blocker that has been approved by the FDA for treatment of hypertension. It has been marketed in Europe since 1999 for treatment of hypertension and heart...
Nebivolol (Bystolic - Forest) is a new beta-blocker that has been approved by the FDA for treatment of hypertension. It has been marketed in Europe since 1999 for treatment of hypertension and heart failure.
Med Lett Drugs Ther. 2008 Mar 10;50(1281):17-9 | Show Full IntroductionHide Full Introduction

Drugs for Migraine

   
The Medical Letter on Drugs and Therapeutics • March 1, 2008;  (Issue 67)
Some drugs for treatment of migraine attacks are listed in table 2 on page 18. Drugs for prevention of migraine are listed in table 3 on page 20. Treatment of migraine in the emergency room, which may involve...
Some drugs for treatment of migraine attacks are listed in table 2 on page 18. Drugs for prevention of migraine are listed in table 3 on page 20. Treatment of migraine in the emergency room, which may involve use of intravenous drugs, is not included here.
Treat Guidel Med Lett. 2008 Mar;6(67):17-22 | Show Full IntroductionHide Full Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • June 1, 2005;  (Issue 34)
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 40. Combination products are listed on page 47. Drugs...
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 40. Combination products are listed on page 47. Drugs for treatment of hypertensive emergencies are not discussed here.
Treat Guidel Med Lett. 2005 Jun;3(34):39-48 | Show Full IntroductionHide Full Introduction

ARBs and Myocardial Infarction

   
The Medical Letter on Drugs and Therapeutics • May 9, 2005;  (Issue 1208)
Angiotensin receptor blockers (ARBs) are widely used as an alternative to angiotensin converting enzyme (ACE) inhibitors for treatment of hypertension because they lower blood pressure without inducing a cough....
Angiotensin receptor blockers (ARBs) are widely used as an alternative to angiotensin converting enzyme (ACE) inhibitors for treatment of hypertension because they lower blood pressure without inducing a cough. It has not been established that they provide the same cardiac benefits as ACE inhibitors. Recently, an editorial in the British Medical Journal suggested that ARBs may increase the risk of myocardial infarction.
Med Lett Drugs Ther. 2005 May 9;47(1208):38-9 | Show Full IntroductionHide Full Introduction

Topiramate (Topamax) for Prevention of Migraine

   
The Medical Letter on Drugs and Therapeutics • January 31, 2005;  (Issue 1201)
Patients with frequent, severe or disabling migraine headaches may benefit from taking a drug to prevent the attacks. Beta-blockers traditionally have been the prophylactic treatment of choice, but in recent...
Patients with frequent, severe or disabling migraine headaches may benefit from taking a drug to prevent the attacks. Beta-blockers traditionally have been the prophylactic treatment of choice, but in recent years some antiepileptic drugs such as valproate (Depakote, and others) and topiramate (Topamax) have also been used for this indication. Valproate was approved by the FDA for such use in 1996. Now topiramate has also been approved.
Med Lett Drugs Ther. 2005 Jan 31;47(1201):9-10 | Show Full IntroductionHide Full Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • February 1, 2003;  (Issue 6)
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the table that begins on page 35. Combination products are listed on page 39. Drugs...
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the table that begins on page 35. Combination products are listed on page 39. Drugs for treatment of hypertensive emergencies were discussed in Treatment Guidelines volume 1, issue 4, page 19, December 2002.
Treat Guidel Med Lett. 2003 Feb;1(6):33-40 | Show Full IntroductionHide Full Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • March 5, 2001;  (Issue 1099)
Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the...
Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.
Med Lett Drugs Ther. 2001 Mar 5;43(1099):17-22 | Show Full IntroductionHide Full Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • March 12, 1999;  (Issue 1048)
Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the...
Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.
Med Lett Drugs Ther. 1999 Mar 12;41(1048):23-8 | Show Full IntroductionHide Full Introduction

New "Triptans" and Other Drugs for Migraine

   
The Medical Letter on Drugs and Therapeutics • October 9, 1998;  (Issue 1037)
Three new 5-HT1 receptors agonissts ('triptans') have been marketed recently for treatment of migraine. Some drugs for prevention of migraine are listed in the table on page 99. Treatment of migraine in the...
Three new 5-HT1 receptors agonissts ('triptans') have been marketed recently for treatment of migraine. Some drugs for prevention of migraine are listed in the table on page 99. Treatment of migraine in the emergency room, which may involve use of intravenous drugs, is not included here.
Med Lett Drugs Ther. 1998 Oct 9;40(1037):97-100 | Show Full IntroductionHide Full Introduction

Drugs for Treatment of Peptic Ulcers

   
The Medical Letter on Drugs and Therapeutics • January 3, 1997;  (Issue 991)
Most peptic ulcers not caused by nonsteroidal anti-inflammatory drugs (NSAIDs) are now thought to be associated with infection of the gastric mucosa by the gram-negative bacilli Helicobacter pylori. The...
Most peptic ulcers not caused by nonsteroidal anti-inflammatory drugs (NSAIDs) are now thought to be associated with infection of the gastric mucosa by the gram-negative bacilli Helicobacter pylori. The majority of NSAID-related ulcers are gastric. H. pylori have been associated with both duodenal and gastric ulcers. Eradication of H. pylori promotes healing and markedly decreases recurrence of both duodenal and gastric ulcers (AH Soll, JAMA, 275:622, 1996).
Med Lett Drugs Ther. 1997 Jan 3;39(991):1-4 | Show Full IntroductionHide Full Introduction

Losartan for Hypertension

   
The Medical Letter on Drugs and Therapeutics • June 23, 1995;  (Issue 951)
Losartan potassium (Cozaar - Merck), the first angiotensin II receptor antagonist, has been approved for oral treatment of hypertension by the US Food and Drug Administration. It will be marketed both alone...
Losartan potassium (Cozaar - Merck), the first angiotensin II receptor antagonist, has been approved for oral treatment of hypertension by the US Food and Drug Administration. It will be marketed both alone and in a fixed-dose combination with the diuretic hydrochlorothiazide (Hyzaar).
Med Lett Drugs Ther. 1995 Jun 23;37(951):57-8 | Show Full IntroductionHide Full Introduction

Drugs for Stable Angina Pectoris

   
The Medical Letter on Drugs and Therapeutics • December 9, 1994;  (Issue 937)
Many nitrates, beta-blockers, and calcium-channel blockers have now been approved by the US Food and Drug Administration for treatment of stable angina pectoris. The table beginning on page 112 lists the...
Many nitrates, beta-blockers, and calcium-channel blockers have now been approved by the US Food and Drug Administration for treatment of stable angina pectoris. The table beginning on page 112 lists the individual drugs, their dosage, and their cost.
Med Lett Drugs Ther. 1994 Dec 9;36(937):111-4 | Show Full IntroductionHide Full Introduction

Doxazosin For Treatment of Hypertension

   
The Medical Letter on Drugs and Therapeutics • February 22, 1991;  (Issue 838)
Doxazosin (mesylate - Roerig), an alpha1-adrenergic receptor blocker similar to prazosin (Minipress, and others) and terazosin (Hytrin), was recently approved by the US Food and Drug Administration for...
Doxazosin (mesylate - Roerig), an alpha1-adrenergic receptor blocker similar to prazosin (Minipress, and others) and terazosin (Hytrin), was recently approved by the US Food and Drug Administration for treatment of hypertension.
Med Lett Drugs Ther. 1991 Feb 22;33(838):15-6 | Show Full IntroductionHide Full Introduction

Betaxolol for Hypertension

   
The Medical Letter on Drugs and Therapeutics • June 29, 1990;  (Issue 821)
Betaxolol (Kerlone - Searle), an oral beta-adrenergic blocker, was recently approved by the US Food and Drug Administration for once-daily treatment of hypertension. The new drug is beta 1 (cardio)-selective...
Betaxolol (Kerlone - Searle), an oral beta-adrenergic blocker, was recently approved by the US Food and Drug Administration for once-daily treatment of hypertension. The new drug is beta 1 (cardio)-selective with no intrinsic sympathomimetic (partial agonist) activity. It is also available in a topical formulation for treatment of glaucoma (Betoptic - Medical Letter, 28:45, 1986). Beta-blockers currently available in the USA for treatment of hypertension are listed in the table below.
Med Lett Drugs Ther. 1990 Jun 29;32(821):61-2 | Show Full IntroductionHide Full Introduction

Carteolol and Penbutolol For Hypertension

   
The Medical Letter on Drugs and Therapeutics • July 28, 1989;  (Issue 797)
Carteolol (Cartrol - Abbott) and penbutolol (Levatol - Reed & Carnrick), two oral beta-adrenergic blocking drugs, were recently approved by the US Food and Drug Administration for once-daily treatment of...
Carteolol (Cartrol - Abbott) and penbutolol (Levatol - Reed & Carnrick), two oral beta-adrenergic blocking drugs, were recently approved by the US Food and Drug Administration for once-daily treatment of systemic hypertension. Both drugs are non-selective beta-blockers with mild partial agonist activity. Beta-blockers currently available in the USA for treatment of hypertension are listed in the table on the next page.
Med Lett Drugs Ther. 1989 Jul 28;31(797):70-1 | Show Full IntroductionHide Full Introduction

Nicardipine - A New Calcium-Entry Blocker

   
The Medical Letter on Drugs and Therapeutics • May 5, 1989;  (Issue 791)
Nicardipine (Cardene - Syntex), a dihydropyridine calcium-entry blocker structurally related to nifedipine (Procardia; Adalat), was recently approved by the US Food and Drug Administration for oral treatment...
Nicardipine (Cardene - Syntex), a dihydropyridine calcium-entry blocker structurally related to nifedipine (Procardia; Adalat), was recently approved by the US Food and Drug Administration for oral treatment of angina and hypertension. Advertisements for the drug claim that nicardipine is more vasoselective; than other calcium-channel blockers and does not depress myocardial contractility.
Med Lett Drugs Ther. 1989 May 5;31(791):41-2 | Show Full IntroductionHide Full Introduction

Lisinopril For Hypertension

   
The Medical Letter on Drugs and Therapeutics • April 8, 1988;  (Issue 763)
- Merck; Zestril - Stuart), a new angiotensin-converting enzyme (ACE) inhibitor, was recently approved by the US Food and Drug Administration (FDA) for once-daily treatment of . Two other ACE inhibitors,...
- Merck; Zestril - Stuart), a new angiotensin-converting enzyme (ACE) inhibitor, was recently approved by the US Food and Drug Administration (FDA) for once-daily treatment of . Two other ACE inhibitors, captopril (Capoten - Squibb) and e
Med Lett Drugs Ther. 1988 Apr 8;30(763):41-2 | Show Full IntroductionHide Full Introduction